AIP
STAB

ARS Investment Partners’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

ARS Investment Partners’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-36,981
Closed -$194K – 152
2021
Q1 		$194K Buy
+36,981
New +$202K 0.02% 133

Other funds holding STAB

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ARS Investment Partners's STAB Position: Q2 2021 in Review

ARS Investment Partners sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2021, closing a stake of 36,981 shares — an estimated $194K sold.

ARS Investment Partners first reported a position in STAB in Q1 2021 and held it in 1 quarter. The position peaked at $194K in Q1 2021. 21 funds tracked by Wall St. Rank hold STAB as of Q2 2021.

  • ARS Investment Partners reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • ARS Investment Partners sold 36,981 Statera Biopharma, Inc. Common Stock shares in Q2 2021, an estimated $194K.
  • ARS Investment Partners first reported a position in Statera Biopharma, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • ARS Investment Partners's Statera Biopharma, Inc. Common Stock position peaked at $194K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2021.

Based on ARS Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.